Antiviral drug

Containing the coronavirus effects on the nervous system

Retrieved on: 
Tuesday, March 23, 2021
Branches of biology, Medical specialties, Immunology, Immune system, Education in Montreal, Institut national de la recherche scientifique, Université du Québec, Cytokines, Antiviral drug, Institut national de recherche et de sécurité, Innate immune system, Protease

Research conducted at the Institut national de la recherche scientifique (INRS) has identified ways to prevent the spread of infection within the central nervous system (CNS).

Key Points: 
  • Research conducted at the Institut national de la recherche scientifique (INRS) has identified ways to prevent the spread of infection within the central nervous system (CNS).
  • The study , led by Professor Pierre Talbot and his research associate Marc Desforges, now at CHU-Sainte-Justine, was published in the Journal of Virology.
  • The research team is the first to make the demonstration of a direct link between neurovirulence, protein S cleavage by cellular proteases and innate immunity.
  • This antiviral immunity arises from the production of interferons, frontline proteins that help to detect early the presence of the virus.

COVID-19 Prevention Disease Analysis Report 2020: Likelihood of Approval of a Phase I Antiviral Asset is 13.3%, and the Average Probability a Drug Advances from Phase III is 68.5% - ResearchAndMarkets.com

Retrieved on: 
Monday, March 22, 2021
Health, General Health, Companies, COVID-19 vaccines, Clinical trials, Health sciences, Health, Medical research, Novavax, Johnson & Johnson COVID-19 vaccine, Sanofi, AstraZeneca, Antiviral drug

The "Disease Analysis: COVID-19 Prevention" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: COVID-19 Prevention" report has been added to ResearchAndMarkets.com's offering.
  • However, pledges from Sanofi, Johnson & Johnson, and AstraZeneca to market vaccines at non-profit prices during the pandemic phase.
  • Fortunately, several more vaccines could launch in 2021, including Novavax's NVX-CoV2373 and Johnson & Johnson's JNJ-78436735, which will substantially boost global supply.
  • Antiviral assets, on average, take 8.5 years from Phase I to approval, slightly shorter than the average of 8.9 years for all infectious disease assets.

Todos Medical Applauds Senate and House Passage of the American Recovery Act

Retrieved on: 
Thursday, March 11, 2021
Medicine, Medical terminology, Antiviral drug, Biocides, Cancer, 3C-like protease, Screening, Health sciences, Health

The US Federal Government is responding appropriately given the scale of the COVID-19 problem we face, said Gerald Commissiong, President & CEO of Todos Medical.

Key Points: 
  • The US Federal Government is responding appropriately given the scale of the COVID-19 problem we face, said Gerald Commissiong, President & CEO of Todos Medical.
  • This funding could also support the commercialization of Todos suite of proprietary 3CL protease diagnostic and screening tests currently in development.
  • The American Recovery Act also intends to boost funding for antiviral solutions that could complement the national vaccination plan.
  • Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.

ACLIV Wins Certification for Killing COVID-19 Virus by 99.9% Within 30 Minutes From Antiviral Testing Agency in France

Retrieved on: 
Thursday, March 11, 2021
Research, Mobile, Wireless, Hardware, Pharmaceutical, Technology, Medical devices, Infectious diseases, Semiconductor, Science, Chemicals, Plastics, Other Technology, Health, Manufacturing, Zoonoses, Health, Articles, Pandemics, Antiviral drug, Biocides, Virus, Coronavirus disease, Influenza A virus subtype H1N1

: 21-1634) from an antiviral testing agency in France, confirming that its antiviral film ACLIV can kill COVID-19 virus by 99.9% within 30 minutes.

Key Points: 
  • : 21-1634) from an antiviral testing agency in France, confirming that its antiviral film ACLIV can kill COVID-19 virus by 99.9% within 30 minutes.
  • At the test conducted targeting the COVID-19 virus, ACLIV antiviral film killed 99.9% of the virus within 30 minutes.
  • This is by far the most outstanding result among those of antiviral tests conducted on the COVID-19 virus so far.
  • Previously, Hexis of France had produced the best result of killing the virus in approximately one hour.

Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX

Retrieved on: 
Wednesday, March 10, 2021
Natural sciences, Physical sciences, Academic disciplines, Cocrystal, Crystallography, Solid-state chemistry, Drug discovery, Combinatorial chemistry, Computational science, Antiviral drug

Through this collaboration, Cocrystal, HitGen and InterX scientists are applying HitGens DNA-encoded library (DEL) technology platform, Cocrystals structure-based drug discovery platform technology, and InterXs computational science to develop novel antiviral lead candidates.

Key Points: 
  • Through this collaboration, Cocrystal, HitGen and InterX scientists are applying HitGens DNA-encoded library (DEL) technology platform, Cocrystals structure-based drug discovery platform technology, and InterXs computational science to develop novel antiviral lead candidates.
  • The DEL technology combines the power of molecular biology, combinatorial chemistry, high throughput sequencing and advanced informatics to identify potential drug candidates.
  • Cocrystal applies its technology to determine the cocrystal structures of the potential drug candidates identified from the DEL library.
  • The economic and unknown impacts of Covid-19 could result in unanticipated material adverse effects on HitGen, InterX or Cocrystal.

Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference

Retrieved on: 
Tuesday, March 9, 2021
Medicine, Health sciences, Sarbecovirus, Health, Epidemiology, Pandemics, Virus, Zoonoses, Antiviral drug, Coronavirus, Cocrystal, Severe acute respiratory syndrome coronavirus

BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021.

Key Points: 
  • BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021.
  • A webcast of Cocrystals presentation has been pre-recorded and is available on the Companys website here .
  • Investors interested in arranging a virtual meeting with Cocrystal management should contact their Roth Capital Partners sales representative or LHA Investor Relations.
  • Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses.

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

Retrieved on: 
Tuesday, March 9, 2021
Health sciences, Health, Medical specialties, Zoonoses, Medical research, Antibodies, Animal virology, Virology, Antiviral drug, Neutralizing antibody, Coronavirus disease, Coronavirus

Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.

Key Points: 
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.
  • Hence, passive antibody immunotherapy with potent and broadly neutralizing molecules like our XVR011, to prevent or suppress viral replication in the lower airways, should find an important place in rescuing Covid-19 patients."
  • Exevir's lead asset XVR011 is a single domain-based anti- Covid-19 antibody (VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.
  • ExeVir Bio is harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses.

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

Retrieved on: 
Tuesday, March 9, 2021
Health sciences, Health, Medical specialties, Zoonoses, Medical research, Antibodies, Animal virology, Virology, Antiviral drug, Neutralizing antibody, Coronavirus disease, Coronavirus

Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.

Key Points: 
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.
  • Hence, passive antibody immunotherapy with potent and broadly neutralizing molecules like our XVR011, to prevent or suppress viral replication in the lower airways, should find an important place in rescuing Covid-19 patients."
  • Exevir's lead asset XVR011 is a single domain-based anti- Covid-19 antibody (VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.
  • ExeVir Bio is harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses.

Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference

Retrieved on: 
Friday, March 5, 2021
Arthritis, Radicular pain, Osteoarthritis, Covi, Antiviral drug, Biology

Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.

Key Points: 
  • Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.
  • SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.
  • ZTlido was approved by the FDA on February 28, 2018.

Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences

Retrieved on: 
Thursday, March 4, 2021
General Health, Pharmaceutical, Health, Medical Supplies, Biocides, Chemical substances, Chemistry, Physical sciences, Disinfectants, Hypochlorous acid, Itch, Anti-inflammatory, Antimicrobial, Antiviral drug

In addition, the presentation was furnished on a current report on Form 8-K with the U.S. Securities and Exchange Commission via EDGAR.

Key Points: 
  • In addition, the presentation was furnished on a current report on Form 8-K with the U.S. Securities and Exchange Commission via EDGAR.
  • The companys products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner.
  • In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties.
  • Sonoma Pharmaceuticals is a trademark or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.